Welcome to our dedicated page for Inmune Bio SEC filings (Ticker: INMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
INmune Bio Inc.'s SEC filings document the disclosure record of a Nasdaq-listed Nevada biotechnology company developing innate-immune therapies. Its filings identify common stock traded under INMB and cover material-event reports, Regulation FD presentations, shareholder letters, clinical and regulatory updates, operating and financial results, and capital-structure disclosures.
Recent 8-K filings include disclosures tied to product-platform communications and a material definitive agreement involving INmune Bio International and Anthony Nolan for the CORDStrom platform. Proxy materials cover shareholder voting and governance matters, while the company’s formal disclosures frame recurring risks and development-stage issues associated with biotechnology research, regulatory pathways, collaborations and financing.
INmune Bio Inc. reports that it remains a clinical-stage company with no product revenue and a net loss of $6.7 million for the six months ended June 30, 2026, a significant improvement from a $34.2 million loss a year earlier, largely due to lower Alzheimer’s program spend and the absence of a prior-year $16.5 million impairment.
Cash and cash equivalents were $18.4 million at June 30, 2026, down from $24.8 million, with $6.6 million used in operating activities in the first half. Management states that existing cash and projected operating needs create substantial doubt about the company’s ability to continue as a going concern for one year after issuance.
The lead program is CORDStrom for recessive dystrophic epidermolysis bullosa, which has completed a pivotal randomized cross-over trial. The company plans to file a Marketing Authorization Application in the UK by late 2026, an EU filing in early 2027, then a BLA with the FDA. INmune Bio also highlights $4.4 million in R&D tax rebates received in the first half and continued access to a $65 million at-the-market equity facility, of which only a small portion has been used.
INmune Bio Inc. reported that on July 30, 2026 it received a research and development cash rebate from Australia of approximately $4.2 million. This payment follows an additional approximately $0.4 million R&D rebate from the United Kingdom during June 2026, for combined rebates of about $4.6 million.
The company states that, after adjusting second-quarter operating cash flows to exclude the UK rebate received during the quarter, the combined rebate proceeds exceeded its net cash used in operating activities for that period. Management describes these rebates as non-dilutive cash that strengthens the balance sheet, extends the cash runway, and supports advancing CORDStrom™ (Ebstrocel™) toward regulatory filings, alongside other late-stage innate immune system programs.
Inmune Bio, Inc. director Juda Scott exercised common stock purchase warrants in a cash transaction, acquiring 14,801 shares of Common Stock at $1.40 per share. This exercise stems from an April 2024 warrant inducement agreement with the company.
Following the transaction, Scott directly owns 86,404 shares of Common Stock. Under the same inducement letter, the maturity date of the remaining 50% of Scott’s April 2024 warrants that were not exercised was extended from June 30, 2026 to December 31, 2027, providing a longer exercise window for those warrants.
INmune Bio, Inc. Chief Scientific Officer Mark William Lowdell exercised common stock purchase warrants to acquire 7,211 shares of Common Stock at an exercise price of $1.40 per share. This increased his directly held stake to 1,518,017 Common shares.
The exercise was part of a warrant inducement arrangement tied to April 2024 Warrants. Lowdell agreed to exercise 50% of his April 2024 Warrants for cash, while the company extended the maturity date of the remaining 50% of those warrants from June 30, 2026 to December 31, 2027.
Inmune Bio, Inc. Chief Executive Officer David J. Moss exercised common stock purchase warrants to acquire 9,014 shares of Common Stock at an exercise price of $1.40 per share in cash. Following this transaction, he directly holds 1,294,883 shares of Common Stock. Under a related warrant inducement offer letter, the remaining 50% of his April 2024 Warrants that were not exercised now have their maturity date extended to December 31, 2027.
INmune Bio Inc. entered into a warrant inducement offer and a warrant amendment with holders of its April 2024 common stock purchase warrants. Holders agreed to exercise 647,112 warrants, representing 50% of their April 2024 Warrants, at a reduced exercise price of $1.40 per share, down from $1.95. INmune Bio expects to receive $905,957 in cash from these exercises. In return, the company extended the maturity date for the remaining 50% of these warrants from June 30, 2026 to December 31, 2027, preserving additional future warrant exercise optionality.
INmune Bio Inc. reported receiving official, accepted meeting minutes from a pre-Marketing Authorization Application Scientific Advice meeting with the UK MHRA for its CORDStrom-derived product Ebstrocel in recessive dystrophic epidermolysis bullosa (RDEB). The minutes document written alignment across all company questions and outline a clear regulatory path for a planned 2026 UK Marketing Authorization Application seeking Conditional Marketing Authorization.
MHRA feedback confirmed the company’s pooled-donor CMC and commercial manufacturing framework, endorsed a focused, literature-supported non-clinical safety strategy, and clarified an evidence approach tailored to ultra-rare RDEB, including openness to Bayesian statistics and patient- and parent-reported outcomes. INmune Bio plans to incorporate endpoint and pediatric population recommendations into a confirmatory Phase 3 program expected to open in 2026, and to use this guidance for future EMA and FDA submissions planned for late 2026 or early 2027.
INmune Bio Inc. reported results from its annual meeting of stockholders. Stockholders approved the Third Amended and Restated 2021 Stock Incentive Plan, increasing the shares of common stock available under the plan from 6,500,000 to 9,158,525, providing more capacity for equity-based awards to directors, officers and employees.
The amended plan also adds an evergreen provision, allowing the share reserve to increase automatically on the first trading day of each calendar year from 2027 through 2031 by the lesser of 10.0% of shares outstanding as of the prior December 31 or a smaller amount set by the board. Stockholders also elected five directors and ratified CBIZ CPAs P.C. as independent auditors for the fiscal year ending December 31, 2026.
INmune Bio Inc. reported new exploratory MRI biomarker results from its MINDFuL Phase 2 trial of XPro™ (XPro1595) in patients with early Alzheimer’s disease. Chi-separation MRI showed a statistically significant treatment effect on white matter myelin in the full modified intent-to-treat population of 200 patients (p=0.0028; d=0.46).
In a biomarker-enriched subgroup of 100 patients with elevated inflammation, the effect strengthened (p=0.0098; d=0.59), supporting the company’s precision-medicine approach and planned Phase 2b/3 registrational program. These data complement prior MINDFuL results, FDA End-of-Phase 2 alignment, FDA Fast Track designation, and a favorable safety profile with no observed ARIA-E or ARIA-H.
INmune Bio Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to XPro™ (pegipanermin), its first-in-class selective soluble TNF inhibitor, for treating early Alzheimer’s disease. The designation covers patients with mild cognitive impairment due to Alzheimer’s and mild Alzheimer’s dementia.
Fast Track status is intended for serious diseases with unmet medical needs and can allow more frequent FDA interactions, Rolling Review and other expedited review tools. INmune plans a Phase 2b/3 seamless adaptive registrational program in biologically confirmed early Alzheimer’s patients with inflammatory biomarkers, using EMACC and plasma pTau217 as decision-gating endpoints before moving to clinical outcome measures such as CDR-SB.